CONTACT
+91 80 2808 2808
info@biocon.com
Biocon  /  Investor Relations  /  Stock Exchange Disclosures  /  Press Release

PRESS RELEASE

March-22
29-Mar University of Glasgow Names their Flagship Research Centre After John Shaw and Kiran Mazumdar-Shaw
23-Mar Kiran Mazumdar-Shaw Elected as the Fellow of Royal Society of Edinburgh (RSE)
February-22
27-Feb Biocon Biologics to Acquire Viatris’ Biosimilars Assets for up to USD 3.335 billion in Stock and Cash
January-22
20-Jan Biocon Q3FY22 Revenue at Rs 2,223 Cr, Up 18%; EBITDA at Rs 537 Cr, Up 25%; Biosimilars Up 28% at Rs 981 Cr; Research Services Up 10% at Rs 641 Cr; Generics Up 7% at Rs 607 Cr
December-21
30-Dec Biocon Biologics* Partner Viatris Wins U.S. Court Decisions on Sanofi Appeals for Lantus® Device Patents
23-Dec Clinical Study for Itolizumab in Lupus Nephritis Initiated in India, Post DCGI Approval
07-Dec Biocon Ltd partners with Tabuk Pharmaceuticals to commercialise its speciality generic medicines in the Middle East
01-Dec Biocon Enters Prestigious Dow Jones Sustainability Emerging Markets Index
November-21
16-Nov Biocon Biologics and Viatris Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection
15-Nov Biocon Biologics Collaborates with RSSDI to Expand Access to its Insulins for Children with Type 1 Diabetes on World Diabetes Day
October-21
21-Oct Biocon Q2FY22 Revenue up 10% at Rs 1,945 Cr; EBITDA up 35% at Rs 551 Cr; Net Profit (before exceptional items) up 11% at Rs 188 Cr;
21-Oct Appointment of Dr. Eric Vivek Mazumdar as Non-Executive, Non-Independent Director of the Company
21-Oct Biocon Biologics’ First-Ever Interchangeable Biosimilar Insulin Glargine, Co-Developed with Commercial Partner Viatris, Preferred on Express Scripts’ Largest Formulary in US
04-Oct Biocon expands its Generic Formulations portfolio with the launch of Everolimus tablets in the US
September-21
16-Sep Biocon Biologics and Serum Institute Life Sciences Announce Strategic Alliance
July-21
29-July Biocon Biologics and Viatris Inc. Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes
26-July Biocon Biologics Partners with Adagio Therapeutics to Advance Antibody for the Prevention and Treatment of COVID-19
22-July Biocon Q1FY22 Revenue at Rs 1,808 Cr, Up 6%; EBITDA at Rs 437 Cr; Biosimilars Up 10 % at Rs 758 Cr; Research Services Up 41 % at Rs 595 Cr;
April-21
29-Apr Biocon Q4FY21 Revenue at Rs 2,044 Cr, Up 26%; EBITDA at Rs 641 Cr; Up 68% Net Profit (before exceptional item & discontinuing operations) at Rs 257 Cr; Biosimilars Up 53% at Rs 664Cr; Research Services Up 8% at Rs 659 Cr; Generics Up 3% at Rs 578 Cr. FY21 Revenue Up 14% at Rs 7,360 Cr; EBITDA Up 8% at Rs 1,907 Cr; Net Profit (before exceptional item & discontinuing operations) at Rs 754 Cr.
28-Apr Biocon Biologics’ New Monoclonal Antibodies Manufacturing Facility Wins ISPE’s 2021 Facility of the Year Honorable Mention Award
Mar-21
29-Mar Biocon Pharma partners with Libbs Farmaceutica to launch generic formulations in Brazil
02-Mar Biocon Biologics Appoints Susheel Umesh as Chief Commercial Officer for Emerging Markets
01-Mar Biocon Biologics Promotes Shreehas Tambe to Deputy Chief Executive Officer
01-Mar Biocon Biologics and Viatris Inc. Receive CHMP Nod for Abevmy®, a Biosimilar to Avastin® (Bevacizumab)
Feb-21
16-Feb Biocon Biologics Joins Hands with IDF in its Mission to Promote Diabetes Care, Prevention and effective Management Worldwide
04-Feb Biocon Biologics to offer its Oncology Biosimilars through Cancer Access Partnership in over 30 countries, Will enable access to Trastuzumab & Pegfilgrastim in Africa & Asia
Jan-21
21-Jan Biocon Q3FY21 Revenue at ₹ 1,879 Crore, Up 7%; EBITDA at ₹427 Crore; Net Profit at ₹169 Crore; Biosimilars up 11% at ₹769 Crore; Research Services up 13% at ₹585 Crore; Generics down 3% at ₹561 Crore
21-Jan Professor Peter Piot Joins the Board of Biocon Biologics Limited as an Independent Director
07-Jan Biocon Biologics Receives Rs 555 Cr (USD 75 Million) Capital Injection from ADQ
Dec-20
28-Dec Biocon expands generic formulations portfolio with the launch of Tacrolimus capsules in the US
15-Dec Biocon Biologics signs an MoU with CSSC in Tanzania for Mission 10 cents
Nov-20
07-Nov Biocon Biologics Receives USD 150 Million Capital Injection from Goldman Sachs, Transaction Values Biocon Biologics at USD 3.94 Billion
Oct-20
30-Oct Biocon Ranked Among Top 5 Biotech Employers Globally
22-Oct Press Release on financial results for the Quarter ended September 30, 2020
08-Oct Biocon Foundation Signs MoU with Bangalore Metro to Contribute Towards Building Metro Station in Hebbagodi
Sep-20
22-Sep Biocon appoints Anupam Jindal as its Chief Financial Officer
Aug-20
31-Aug Biocon Biologics and Mylan Announce Launch of Semglee™ (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes
14-Aug Disclosure of material impact of COVID 19 pandemic on the Company
03-Aug Execution of SHA and SSA with Tata Capital Growth Fund II – Disclosure pursuant to Regulation 30 of SEBI Regulations, 2015
Jul-20
31-Jul Tata Capital Growth Fund to Invest ~USD 30 Million (Rs 225 Crore) in Biocon Biologics for an Equity Stake of 0.85%, Deal Values Biocon Biologics at USD 3.5 Billion
23-Jul Press Release on financial results for the quarter ended June 30, 2020.
21-Jul Biocon Biologics and Voluntis Join Hands for Global Collaboration on Digital Therapeutics for Insulins
11-Jul Biocon’s Breakthrough Drug Itolizumab Receives DCGI Nod for its Use in Moderate to Severe COVID-19 Patients
Jun-20
22-Jun Biocon Pharma and DKSH Collaborate to commercialize seven generic formulations in South East Asia markets
12-Jun Biocon and Mylan Announce U.S. FDA Approval of Semglee™ (insulin glargine injection)
05-Jun Kiran Mazumdar-Shaw wins EY World Entrepreneur of the Year™ 2020 Award. She is the first woman entrepreneur from India and third Indian to win this title in WEOY Award’s 20-year History
01-Jun Biocon’s* Partner Mylan Receives Favourable Ruling from U.S. PTAB on Sanofi’s Four Device Patents for Lantus® SoloSTAR®
May-20
27-May Biocon Biologics Receives DCGI Approval for Emergency Use of CytoSorb® to Treat Critical COVID-19 Patients U.S. FDA recently approved CytoSorb for emergency use in COVID-19 patients
19-May Biocon Biologics Receives EU GMP Certification for Multiple Biosimilars Manufacturing Facilities in Bengaluru; Expands its Manufacturing Capacity Includes Drug Substance and Drug Product Facilities for Pegfilgrastim, Trastuzumab, and Bevacizumab
14-May Biocon Earnings Q4FY20 Revenue Up 6% at Rs 1,644 Cr; EBITDA Down 11% at Rs 382 Cr; Net Profit Down 42% at Rs 123 Cr
Apr-20
28-Apr Biocon and Mylan Launch Fulphila®d, Biosimilar Pegfilgrastim, in Canada.
14-Apr Biocon and Mylan Launch Fulphila®, Biosimilar Pegfilgrastim, in Australia
01-Apr Biocon’s Insulin Manufacturing Facility in Malaysia Receives EIR from U.S. FDA with Voluntary Action Indicated (VAI) Classification, Inspection Stands Closed

FY: From April 1 – March 31

NOVEL BIOLOGICS
BIOSIMILARS
RESEARCH SERVICES
OUR CULTURE
BIOCON FOUNDATION
Share
Previous Next
Close
Test Caption
Test Description goes like this